top of page

X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page